United Therapeutics CEO sold 9,500 shares under plan

Posted by Alphonse Anthony on Oct 1st, 2026

What happened

Martine A. Rothblatt, chairperson, CEO and a director of United Therapeutics Corp (NASDAQ: UTHR), sold 9,500 shares on 2026-09-28. She sold them at prices from $472.43 to $486.00 per share, for about $4.57 million in total. The Form 4 says the trades were made under a Rule 10b5-1 trading plan adopted on November 7, 2025.

The filing also shows Rothblatt exercised 9,500 stock options at $117.76 a share before the sale. After the sale, Rothblatt held 324,443 shares. The reported ownership was indirect through a trust, and the derivative table also shows 347,410 stock options beneficially owned afterward in the trust.

Key numbers

Metric	Latest	Source
Shares sold	9,500 shares	SEC Form 4
Sale price range	from $472.43 to $486.00 per share	SEC Form 4
Total sale value	about $4.57 million	SEC Form 4
Shares held after sale	324,443 shares	SEC Form 4
Shares held before sale	333,943 shares	SEC Form 4

Read more: United Therapeutics (UTHR) stock analysis and investment case

Why it matters

OptimistFi's case is that United Therapeutics depends on Tyvaso-led pulmonary hypertension cash flows proving durable enough to fund the next growth leg before competition or pricing pressure erodes the franchise. This filing is mixed for that view because it shows a sizable insider sale, but the pre-arranged plan limits how much timing alone can tell investors. The 9,500 shares were about 2.8% of Rothblatt's 333,943-share holding before the trade.

The sale value was about $4.57 million, which is a real reduction in exposure even though Rothblatt still held 324,443 shares afterward. At that size, the filing is a reminder of insider activity, not evidence that the operating story has changed. The trust holdings show the sale sat inside a much larger family position. That makes the filing a limited signal, not a change in the operating thesis.

Browse: stock research on every company OptimistFi covers

What's next

The plan will continue until the earlier of 1,734,410 stock options being exercised or December 31, 2026. The filing says the exercised options expire on March 15, 2027, so the plan's end comes first. The 1,734,410-option cap sets the outer bound on this arrangement's remaining activity.

An end at year-end would keep the sale signal tied to a fixed schedule, while an earlier stop would show the plan hit its cap sooner. If the cap is reached before year-end, any further insider sales under this plan would stop with it. December 31, 2026 is the filing's next dated endpoint.